Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank:DB08915_nanopub.RAZJaiGwkSHtpPk05A3lZnv4kYA0xIUHe9vn8yI7kJdTY#assertion>. }
Showing items 1 to 16 of
16
with 100 items per page.
- drugbank:DB08915 type drugbank_vocabulary:Drug assertion.
- drugbank:DB08915 label "Aleglitazar [drugbank:DB08915]" assertion.
- drugbank:DB08915 seeAlso DB08915 assertion.
- drugbank:DB08915 identifier "drugbank:DB08915" assertion.
- drugbank:DB08915 description "Aleglitazar is an investigational drug from the company Hoffmann–La Roche and is currently in a phase III clinical trial called ALECARDIO. It is being investigated for use in patients with type II diabetes to reduce their risks of cardiovascular mortality and morbidity. Aleglitazar is an agonist at the peroxisome proliferator-activated receptor (PPAR) for both the PPARα and PPARγ receptor subtypes. In the phase II clinical trial called SYNCHRONY, with type II diabetic patients, aleglitazar was able to control both lipid and glucose levels in a synergistic manner while also having limited side effects and toxicity." assertion.
- drugbank:DB08915 title "Aleglitazar" assertion.
- drugbank:DB08915 bio2rdf_vocabulary:identifier "DB08915" assertion.
- drugbank:DB08915 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB08915 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB08915" assertion.
- drugbank:DB08915 bio2rdf_vocabulary:x-identifiers.org DB08915 assertion.
- drugbank:DB08915 drugbank_vocabulary:drugbank-id "DB08483" assertion.
- drugbank:DB08915 drugbank_vocabulary:drugbank-id "DB08915" assertion.
- drugbank:DB08915 drugbank_vocabulary:x-cas cas:475479-34-6 assertion.
- drugbank:DB08915 drugbank_vocabulary:x-pdb pdb:RO7 assertion.
- drugbank:DB08915 drugbank_vocabulary:x-kegg kegg:D08845 assertion.
- drugbank:DB08915 drugbank_vocabulary:x-wikipedia wikipedia:Aleglitazar assertion.